-
1
-
-
0025866982
-
Anti-human immunodeficiency virus type I activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog
-
1. Soudeyns H, Yao XJ, Gao Q. et al. Anti-human immunodeficiency virus type I activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991; 35: 1386-90
-
(1991)
Antimicrob Agents Chemother
, vol.35
, pp. 1386-1390
-
-
Soudeyns, H.1
Yao, X.J.2
Gao, Q.3
-
2
-
-
0026541703
-
The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro
-
2. Coates JA, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992; 36: 202-5
-
(1992)
Antimicrob Agents Chemother
, vol.36
, pp. 202-205
-
-
Coates, J.A.1
Cammack, N.2
Jenkinson, H.J.3
-
3
-
-
0027431843
-
The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2′,3′-dideoxy-3′-thiacytidine
-
3. Skalski V, Chang CN, Dutschman G, et al. The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2′,3′-dideoxy-3′-thiacytidine. J Biol Chem 1993; 268: 23234-8
-
(1993)
J Biol Chem
, vol.268
, pp. 23234-23238
-
-
Skalski, V.1
Chang, C.N.2
Dutschman, G.3
-
4
-
-
0026740310
-
Cellular metabolism of (-)-enantomeric 2′-deoxy-3′-thiacytidine
-
May 28
-
4. Cammack N, Rouse P, Marr CLP, et al. Cellular metabolism of (-)-enantomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol 1992 May 28; 43 (10): 2059-64
-
(1992)
Biochem Pharmacol
, vol.43
, Issue.10
, pp. 2059-2064
-
-
Cammack, N.1
Rouse, P.2
Marr, C.L.P.3
-
5
-
-
0003319295
-
Pharmacokinetics (PK) of lamivudine (3TC) phosphorylation on periopheral blood mammalian cells (PBMC) from HIV-infected patients
-
Jun 28-Jul 3: Geneva
-
th International Conference on AIDS; 1998 Jun 28-Jul 3: Geneva
-
(1998)
th International Conference on AIDS
-
-
Moore, K.H.P.1
-
6
-
-
0026507919
-
(-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vilro
-
6. Coates JA, Cammack N, Jenkinson HJ, et al. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vilro. Antimicrob Agents Chemother 1992: 36: 733-9
-
(1992)
Antimicrob Agents Chemother
, vol.36
, pp. 733-739
-
-
Coates, J.A.1
Cammack, N.2
Jenkinson, H.J.3
-
7
-
-
0026469165
-
The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxanthiolan-5-y1] cytosine
-
7. Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxanthiolan-5-y1] cytosine. Antimicrob Agents Chemother 1992; 36: 2686-92
-
(1992)
Antimicrob Agents Chemother
, vol.36
, pp. 2686-2692
-
-
Furman, P.A.1
Davis, M.2
Liotta, D.C.3
-
8
-
-
0026697262
-
Deoxycytidine deaminase-resistant stereoisomer is the active form of (-)-2′3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication
-
8. Chang C-N, Doong S-L, Zhou JH, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (-)-2′3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992; 267: 13938-42
-
(1992)
J Biol Chem
, vol.267
, pp. 13938-13942
-
-
Chang, C.-N.1
Doong, S.-L.2
Zhou, J.H.3
-
9
-
-
0029028067
-
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
-
9. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-9
-
(1995)
Science
, vol.269
, pp. 696-699
-
-
Larder, B.A.1
Kemp, S.D.2
Harrigan, P.R.3
-
10
-
-
0027285372
-
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
-
Jun 15
-
10. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993 Jun 15; 90: 5653-6
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 5653-5656
-
-
Tisdale, M.1
Kemp, S.D.2
Parry, N.R.3
-
11
-
-
8944256865
-
Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
-
11. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10: 975-81
-
(1996)
AIDS
, vol.10
, pp. 975-981
-
-
Kuritzkes, D.R.1
Quinn, J.B.2
Benoit, S.L.3
-
12
-
-
26844572356
-
3)
-
Infectious Diseases Society of America; 1996 Jun 28-Feb 1 : Washington, DC. Alexandria, VA: Infectious Diseases Society of America for the Foundation for Retrovirology and Human Health
-
3) [abstract 321]. In: Programs and Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections; Infectious Diseases Society of America; 1996 Jun 28-Feb 1 : Washington, DC. Alexandria, VA: Infectious Diseases Society of America for the Foundation for Retrovirology and Human Health, 1996: 113
-
(1996)
Programs and Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections
, pp. 113
-
-
Johnson, V.A.1
Quinn, J.B.2
Benoit, S.L.3
-
13
-
-
0029035638
-
Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1
-
13. Boyer PL, Hughes SH. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995; 39: 1624-8
-
(1995)
Antimicrob Agents Chemother
, vol.39
, pp. 1624-1628
-
-
Boyer, P.L.1
Hughes, S.H.2
-
14
-
-
0030808934
-
Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials
-
14. Wainberg MA. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. Leukemia 1997; 11 Suppl. 3): 85-8
-
(1997)
Leukemia
, Issue.11 SUPPL. 3
, pp. 85-88
-
-
Wainberg, M.A.1
-
15
-
-
0028783393
-
Mitochondrial toxicity - New adverse drug effects
-
15. Swartz MN. Mitochondrial toxicity - new adverse drug effects. N Engl J Med 1995; 333: 1146-8
-
(1995)
N Engl J Med
, vol.333
, pp. 1146-1148
-
-
Swartz, M.N.1
-
16
-
-
0026651622
-
Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases α, β, and γ
-
16. Hart GJ, Orr DC, Penn CR, et al. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases α, β, and γ. Antimicrob Agents Chemother 1992; 36: 1688-94
-
(1992)
Antimicrob Agents Chemother
, vol.36
, pp. 1688-1694
-
-
Hart, G.J.1
Orr, D.C.2
Penn, C.R.3
-
17
-
-
0030899204
-
Lamivudine: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection
-
17. Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997; 53 (4): 657-80
-
(1997)
Drugs
, vol.53
, Issue.4
, pp. 657-680
-
-
Perry, C.M.1
Faulds, D.2
-
18
-
-
0026471558
-
Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells
-
18. Sommadossi JP, Schinazi RF, Chu CK, Xie MY. Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells. Biochem Pharmacol 1992; 44: 1921-5
-
(1992)
Biochem Pharmacol
, vol.44
, pp. 1921-1925
-
-
Sommadossi, J.P.1
Schinazi, R.F.2
Chu, C.K.3
Xie, M.Y.4
-
19
-
-
0029563673
-
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter
-
Dec 21
-
19. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter. N Engl J Med 1995 Dec 21; 333 (25): 1662-9
-
(1995)
N Engl J Med
, vol.333
, Issue.25
, pp. 1662-1669
-
-
Eron, J.J.1
Benoit, S.L.2
Jemsek, J.3
-
20
-
-
0030215471
-
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection
-
Aug 1
-
20. Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann Intern Med 1996 Aug 1; 125 (3): 161-72
-
(1996)
Ann Intern Med
, vol.125
, Issue.3
, pp. 161-172
-
-
Bartlett, J.A.1
Benoit, S.L.2
Johnson, V.A.3
-
21
-
-
8944225025
-
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviralnaive patients: A randomized controlled comparison with zidovudine monotherapy
-
Jul 10
-
21. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviralnaive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996 Jul 10; 276 (2): 118-25
-
(1996)
JAMA
, vol.276
, Issue.2
, pp. 118-125
-
-
Katlama, C.1
Ingrand, D.2
Loveday, C.3
-
22
-
-
8944245852
-
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: A randomized controlled comparison with zidovudine monotherapy
-
Jul 10
-
22. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996 Jul 10; 276 (2): 111-7
-
(1996)
JAMA
, vol.276
, Issue.2
, pp. 111-117
-
-
Staszewski, S.1
Loveday, C.2
Picazo, J.J.3
-
23
-
-
0030979361
-
Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the international AIDS society - USA Panel
-
Jun 25
-
23. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA Panel. JAMA 1997 Jun 25; 277 (24): 1962-9
-
(1997)
JAMA
, vol.277
, Issue.24
, pp. 1962-1969
-
-
Carpenter, C.C.J.1
Fischl, M.A.2
Hammer, S.M.3
-
24
-
-
0030997937
-
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
-
May 17
-
24. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997 May 17; 349: 1413-21
-
(1997)
Lancet
, vol.349
, pp. 1413-1421
-
-
-
25
-
-
0002461446
-
Durable effect of VIRACEPT (nelfinavir mesylate, NFV) in triple combination therapy
-
American Society of Microbiology; 1997Sep 28-Oct 1: Toronto. Washington, DC: American Society of Microbiology
-
25. Saag M, Knowles M, Chang Y, et al. Durable effect of VIRACEPT (nelfinavir mesylate, NFV) in triple combination therapy [abstract I-101]. In: Program and Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy; American Society of Microbiology; 1997Sep 28-Oct 1: Toronto. Washington, DC: American Society of Microbiology, 1997: 261-2
-
(1997)
Program and Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy
, pp. 261-262
-
-
Saag, M.1
Knowles, M.2
Chang, Y.3
-
26
-
-
0442268112
-
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
-
26. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
-
(1997)
N Engl J Med
, vol.337
, pp. 725-733
-
-
Hammer, S.M.1
Squires, K.E.2
Hughes, M.D.3
-
27
-
-
0030869269
-
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
-
27. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9
-
(1997)
N Engl J Med
, vol.337
, pp. 734-739
-
-
Gulick, R.M.1
Mellors, J.W.2
Havlir, D.3
-
28
-
-
0013482777
-
Combivir™, a fixed dose formulation of lamivudine (3TC) 150 mg and zidovudine (ZDV) 300 mg, given BID plus a protease inhibitor (PI) compared to 3TC 150 mg BID and ZDV 200 mg TID plus a PI
-
Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health
-
28. Eron J, Yetzer E, Poertz D, et al. Combivir™, a fixed dose formulation of lamivudine (3TC) 150 mg and zidovudine (ZDV) 300 mg, given BID plus a protease inhibitor (PI) compared to 3TC 150 mg BID and ZDV 200 mg TID plus a PI [abstract no. 387c]. In: Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1998: 151
-
(1998)
Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections
, pp. 151
-
-
Eron, J.1
Yetzer, E.2
Poertz, D.3
-
29
-
-
0013480903
-
Phase 3 study of the antiviral activity of AZT and 3TC given as separate regimens versus a new fixed dose combination (combivir™)
-
Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health
-
29. Rozenbaum W, Chauveau E. Phase 3 study of the antiviral activity of AZT and 3TC given as separate regimens versus a new fixed dose combination (Combivir™) [abstract no. 669]. In: Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1998: 205
-
(1998)
Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections
, pp. 205
-
-
Rozenbaum, W.1
Chauveau, E.2
-
30
-
-
0030567824
-
Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
-
30. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91
-
(1996)
Lancet
, vol.348
, pp. 283-291
-
-
-
31
-
-
10144244674
-
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
-
31. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335 (15): 1081-90
-
(1996)
N Engl J Med
, vol.335
, Issue.15
, pp. 1081-1090
-
-
Hammer, S.M.1
Katzenstein, D.A.2
Hughes, M.D.3
-
32
-
-
0030862080
-
Alteration of the dismal natural history of fibrosing choleostatic hepatitis secondary to hepatitis B virus with the use of lamivudine
-
32. Al Faraidy K, Yoshida EM, Davis JE, et al. Alteration of the dismal natural history of fibrosing choleostatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997; 64 (6): 926-8
-
(1997)
Transplantation
, vol.64
, Issue.6
, pp. 926-928
-
-
Al Faraidy, K.1
Yoshida, E.M.2
Davis, J.E.3
-
33
-
-
0029591574
-
A preliminary trial of lamivudine for chronic hepatitis B infection
-
Dec 21
-
33. Deinstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995 Dec 21; 333 (25): 1657-61
-
(1995)
N Engl J Med
, vol.333
, Issue.25
, pp. 1657-1661
-
-
Deinstag, J.L.1
Perrillo, R.P.2
Schiff, E.R.3
-
34
-
-
0031021902
-
Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
-
Jan
-
34. Lai C-L, ChingC-K, Tung AK-M, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997 Jan; 25 (1): 241-4
-
(1997)
Hepatology
, vol.25
, Issue.1
, pp. 241-244
-
-
Lai, C.-L.1
Ching, C.-K.2
Tung, A.K.-M.3
-
35
-
-
0030772798
-
Lamivudine therapy for chronic hepatitis B - A six-month randomized dose-ranging study
-
Oct
-
35. Nevens F, Main J, Hoonkoop P, et al. Lamivudine therapy for chronic hepatitis B - a six-month randomized dose-ranging study. Gastroenterology 1997 Oct; 113 (4): 1258-63
-
(1997)
Gastroenterology
, vol.113
, Issue.4
, pp. 1258-1263
-
-
Nevens, F.1
Main, J.2
Hoonkoop, P.3
-
36
-
-
0030989328
-
Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B
-
36. Vanthiel DH, Friedlander L, Kania RJ, et al. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology 1997; 44 (15): 808-12
-
(1997)
Hepatogastroenterology
, vol.44
, Issue.15
, pp. 808-812
-
-
Vanthiel, D.H.1
Friedlander, L.2
Kania, R.J.3
-
37
-
-
0031037065
-
Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
-
37. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B -virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2
-
(1997)
Lancet
, vol.349
, pp. 20-22
-
-
Bartholomew, M.M.1
Jansen, R.W.2
Jeffers, L.J.3
-
38
-
-
0031780935
-
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
-
38. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27 (6): 1670-7
-
(1998)
Hepatology
, vol.27
, Issue.6
, pp. 1670-1677
-
-
Allen, M.I.1
Deslauriers, M.2
Andrews, C.W.3
-
39
-
-
0028575676
-
Interspecies scaling and pharmacokinetic parameters of 3TC in humans
-
Oct
-
39. Hussey EK, Donn KH, Daniel MJ, et al. Interspecies scaling and pharmacokinetic parameters of 3TC in humans. J Clin Pharmacol 1994 Oct; 34: 975-7
-
(1994)
J Clin Pharmacol
, vol.34
, pp. 975-977
-
-
Hussey, E.K.1
Donn, K.H.2
Daniel, M.J.3
-
40
-
-
0027074279
-
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: A phase I study
-
Dec
-
40. van Leeuwen R, Lange JMA, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992 Dec; 6: 1417-25
-
(1992)
AIDS
, vol.6
, pp. 1417-1425
-
-
Van Leeuwen, R.1
Lange, J.M.A.2
Hussey, E.K.3
-
41
-
-
0029591139
-
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine
-
Dec
-
41. Yuen GJ, Morris DM, Mydlow PK, et al. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol 1995 Dec; 35: 1174-80
-
(1995)
J Clin Pharmacol
, vol.35
, pp. 1174-1180
-
-
Yuen, G.J.1
Morris, D.M.2
Mydlow, P.K.3
-
42
-
-
0031831657
-
Single-dose pharmacokinetics of lamivudine in subjects with impaired renal function and effect of haemodialysis
-
42. Johnson MA, Verpooten GA, Daniel MJ, et al. Single-dose pharmacokinetics of lamivudine in subjects with impaired renal function and effect of haemodialysis. Br J Clin Pharmacol 1998; 46: 21-7
-
(1998)
Br J Clin Pharmacol
, vol.46
, pp. 21-27
-
-
Johnson, M.A.1
Verpooten, G.A.2
Daniel, M.J.3
-
43
-
-
0003979209
-
-
Glaxo Wellcome Incorporated
-
43. Data on file. Glaxo Wellcome Incorporated
-
Data on File
-
-
-
44
-
-
0013482691
-
Bioequivalence of combivir™ tablet and epivir® plus retrovir tablets
-
Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health
-
44. Moore KHP, Lloyd PP, Duncan B, et al. Bioequivalence of Combivir™ tablet and Epivir® plus Retrovir tablets [abstract no. 671]. In: Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1998: 205
-
(1998)
Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections
, pp. 205
-
-
Moore, K.H.P.1
Lloyd, P.P.2
Duncan, B.3
-
45
-
-
0029900659
-
Pharmacokinetics of lamivudine administered alone and with trimethoprimsulfamethoxazole
-
May
-
45. Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprimsulfamethoxazole. Clin Pharmacol Ther 1996 May; 59 (5): 550-8
-
(1996)
Clin Pharmacol Ther
, vol.59
, Issue.5
, pp. 550-558
-
-
Moore, K.H.1
Yuen, G.J.2
Raasch, R.H.3
-
46
-
-
0027216366
-
Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients
-
Aug
-
46. Angel JB, Hussey EK, Hall ST, et al. Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients. Drug Invest 1993 Aug; 6: 70-4
-
(1993)
Drug Invest
, vol.6
, pp. 70-74
-
-
Angel, J.B.1
Hussey, E.K.2
Hall, S.T.3
-
47
-
-
0029952016
-
Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction
-
47. Heald AE, Hsyu PH, Yuen GJ, et al. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996; 40 (6): 1514-8
-
(1996)
Antimicrob Agents Chemother
, vol.40
, Issue.6
, pp. 1514-1518
-
-
Heald, A.E.1
Hsyu, P.H.2
Yuen, G.J.3
-
48
-
-
0031818475
-
The pharmacokinetics of lamivudine in patients with impaired hepatic function
-
48. Johnson MA, Horak J, Breuel PB. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol 1998; 54: 363-6
-
(1998)
Eur J Clin Pharmacol
, vol.54
, pp. 363-366
-
-
Johnson, M.A.1
Horak, J.2
Breuel, P.B.3
-
49
-
-
0028356833
-
High-performance liquid chromatographic assay for (-)-2′-deoxy-3′-thiacytidine in human serum
-
Jul 1
-
49. Harker AJ, Evans GL, Hawley AE, Morris DM. High-performance liquid chromatographic assay for (-)-2′-deoxy-3′-thiacytidine in human serum. J Chromatogr B: Biomed Appl 1994 Jul 1; 657 (1): 227-32
-
(1994)
J Chromatogr B: Biomed Appl
, vol.657
, Issue.1
, pp. 227-232
-
-
Harker, A.J.1
Evans, G.L.2
Hawley, A.E.3
Morris, D.M.4
-
50
-
-
0028269179
-
Determination of 2′-deoxy-3′-thiacytidine (3TC) in human urine by liquid chromatography: Direct injection with column switching
-
50. Morris DM, Selinger K. Determination of 2′-deoxy-3′-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching. J Pharm Biomed Anal 1994; 12 (2):255-64
-
(1994)
J Pharm Biomed Anal
, vol.12
, Issue.2
, pp. 255-264
-
-
Morris, D.M.1
Selinger, K.2
-
51
-
-
0013557085
-
Analysis of potential gender differences in lamivudine (3TC) disposition using population pharmacokinetics from two Phase III clinical trials in HIV-infected patients
-
National Conference on Women and HIV; May 4-7: Los Angeles
-
51. Moore KHP, Yuen GJ, Hussey EK. Analysis of potential gender differences in lamivudine (3TC) disposition using population pharmacokinetics from two Phase III clinical trials in HIV-infected patients [abstract 1298]. In: Abstract Book of the National Conference on Women and HIV; National Conference on Women and HIV; 1997 May 4-7: Los Angeles
-
(1997)
Abstract Book of the National Conference on Women and HIV
-
-
Moore, K.H.P.1
Yuen, G.J.2
Hussey, E.K.3
-
52
-
-
0028997078
-
A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection
-
52. Pluda JM, Cooley TP, Montaner JSG, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995; 171 (6): 1438-47
-
(1995)
J Infect Dis
, vol.171
, Issue.6
, pp. 1438-1447
-
-
Pluda, J.M.1
Cooley, T.P.2
Montaner, J.S.G.3
-
53
-
-
19244362628
-
Lamivudine in children with immunodeficiency virus infection: A phase I/II study
-
53. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with immunodeficiency virus infection: a phase I/II study. J Infect Dis 1996; 174 (1): 16-25
-
(1996)
J Infect Dis
, vol.174
, Issue.1
, pp. 16-25
-
-
Lewis, L.L.1
Venzon, D.2
Church, J.3
-
54
-
-
0000312283
-
The pharmacokinetics of 3TC administered to HIV-1 infected women (pre-partum, during labour and post-partum) and their offspring
-
International AIDS Society; 1996 Jul 7-12: Vancouver: International AIDS Society
-
54. Johnson MA, Goodwin C, Yuen GJ, et al. The pharmacokinetics of 3TC administered to HIV-1 infected women (pre-partum, during labour and post-partum) and their offspring [abstract no. Tu.C.445]. In: Program and Abstracts of the 11th International Conference on AIDS; International AIDS Society; 1996 Jul 7-12: Vancouver: International AIDS Society, 1996: 249-50
-
(1996)
Program and Abstracts of the 11th International Conference on AIDS
, pp. 249-250
-
-
Johnson, M.A.1
Goodwin, C.2
Yuen, G.J.3
-
55
-
-
0026669787
-
Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex
-
55. Dudley MN, Graham K, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166: 480-5
-
(1992)
J Infect Dis
, vol.166
, pp. 480-485
-
-
Dudley, M.N.1
Graham, K.2
Kaul, S.3
-
56
-
-
0028911385
-
Clinical pharmacokinetics of nucleoside antiretroviral agents
-
56. Dudley MN. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995; 171: Suppl. 2: S99-112
-
(1995)
J Infect Dis
, vol.171
, Issue.SUPPL. 2
-
-
Dudley, M.N.1
-
57
-
-
0028948198
-
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: A phase I/II study
-
May
-
57. van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995 May; 171: 1166-71
-
(1995)
J Infect Dis
, vol.171
, pp. 1166-1171
-
-
Van Leeuwen, R.1
Katlama, C.2
Kitchen, V.3
-
58
-
-
0028889357
-
Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of non-human primates
-
Dec
-
58. Blaney SM, Daniel MJ, Harker AJ, et al. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of non-human primates. Antimicrob Agents Chemother 1995 Dec; 39 (12): 2779-82
-
(1995)
Antimicrob Agents Chemother
, vol.39
, Issue.12
, pp. 2779-2782
-
-
Blaney, S.M.1
Daniel, M.J.2
Harker, A.J.3
-
59
-
-
0031723646
-
Pharmacokinetics and antiretroviral activity of lamividine alone or when co-administered with zidovudine in HIV-infected pregnant women and their offspring
-
59. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamividine alone or when co-administered with zidovudine in HIV-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-33
-
(1998)
J Infect Dis
, vol.178
, pp. 1327-1333
-
-
Moodley, J.1
Moodley, D.2
Pillay, K.3
-
60
-
-
0000535079
-
Pharmacokinetics of oral lamivudine administered alone and with oral zidovudine (ZDV) in asymptomatic patients with human immunodeficiency virus (HIV) infection
-
Feb
-
60. Horton CM, Yuen G, Mikolich DM, et al. Pharmacokinetics of oral lamivudine administered alone and with oral zidovudine (ZDV) in asymptomatic patients with human immunodeficiency virus (HIV) infection [abstract no. PIII-64]. Clin Pharmacol Ther 1994 Feb; 55 (2): 198
-
(1994)
Clin Pharmacol Ther
, vol.55
, Issue.2
, pp. 198
-
-
Horton, C.M.1
Yuen, G.2
Mikolich, D.M.3
-
61
-
-
0030776777
-
Lamivudine (3TC) phosphorylation and drug interactions in vitro
-
61. Kewn S, Veal GJ, Hoogard PC, et al. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol 1997; 54: 589-95
-
(1997)
Biochem Pharmacol
, vol.54
, pp. 589-595
-
-
Kewn, S.1
Veal, G.J.2
Hoogard, P.C.3
-
62
-
-
0028300765
-
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells
-
62. Gao WY, Agbaria R, Driscoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269 (17): 12633-8
-
(1994)
J Biol Chem
, vol.269
, Issue.17
, pp. 12633-12638
-
-
Gao, W.Y.1
Agbaria, R.2
Driscoll, J.S.3
-
63
-
-
0013515054
-
Pharmacokinetics of lamivudine in chronic hepatitis B virus-infected patients undergoing liver transplantation
-
American Society of Microbiology; 1997 Sep 28-Oct 1: Toronto. Washington, DC: American Society of Microbiology
-
63. Johnson MA, Mutimer D, Ahmed M, et al. Pharmacokinetics of lamivudine in chronic hepatitis B virus-infected patients undergoing liver transplantation [abstract no. A-47]. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; American Society of Microbiology; 1997 Sep 28-Oct 1: Toronto. Washington, DC: American Society of Microbiology, 1997: 9
-
(1997)
Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy
, pp. 9
-
-
Johnson, M.A.1
Mutimer, D.2
Ahmed, M.3
-
64
-
-
0029415188
-
Renal disposition and drug interaction screening of (-)-2′-deoxy-3′-thiacytidine (3TC) in the isolated perfused rat kidney
-
Dec
-
64. Sweeney KR, Hsyu P-H, Statkevich P, et al. Renal disposition and drug interaction screening of (-)-2′-deoxy-3′-thiacytidine (3TC) in the isolated perfused rat kidney. Pharmaceut Res 1995 Dec; 12(12): 1958-63
-
(1995)
Pharmaceut Res
, vol.12
, Issue.12
, pp. 1958-1963
-
-
Sweeney, K.R.1
Hsyu, P.-H.2
Statkevich, P.3
-
65
-
-
0013520977
-
Effect of lamivudine on zidovudine pharmacokinetics in asymptomatic HIV-infected individuals
-
American Society of Microbiology; 1994 Oct 4-7; Orlando (FL). Washington, DC: American Society of Microbiology
-
65. Rana KZ, Horton CM, Yuen GJ, et al. Effect of lamivudine on zidovudine pharmacokinetics in asymptomatic HIV-infected individuals [abstract no. A62]. In: Program and abstracts of the 34th Interscicnce Conference on Antimicrobial Agents and Chemotherapy; American Society of Microbiology; 1994 Oct 4-7; Orlando (FL). Washington, DC: American Society of Microbiology, 1994: 83
-
(1994)
Program and Abstracts of the 34th Interscicnce Conference on Antimicrobial Agents and Chemotherapy
, pp. 83
-
-
Rana, K.Z.1
Horton, C.M.2
Yuen, G.J.3
-
66
-
-
0001964670
-
The safety and pharmacokinetics of GW1592U89, zidovudine and lamivudine (3TC) alone and in combination after single-dose administration in HIV-infected patients
-
66. Symonds WT, McDowell J, Chittick G, et al. The safety and pharmacokinetics of GW1592U89, zidovudine and lamivudine (3TC) alone and in combination after single-dose administration in HIV-infected patients [abstract]. AIDS 1996; 10 Suppl. 2: S23
-
(1996)
AIDS
, vol.10
, Issue.SUPPL. 2
-
-
Symonds, W.T.1
McDowell, J.2
Chittick, G.3
-
67
-
-
0032101831
-
Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: Results of a pilot study
-
67. Mutimer D, Naoumov N, Honkoop P, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998; 28: 923-9
-
(1998)
J Hepatol
, vol.28
, pp. 923-929
-
-
Mutimer, D.1
Naoumov, N.2
Honkoop, P.3
-
68
-
-
0029869720
-
Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation
-
May
-
68. Veal GJ, Hoggard PG, Barry MG, et al. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS 1996 May; 10 (5): 546-8
-
(1996)
AIDS
, vol.10
, Issue.5
, pp. 546-548
-
-
Veal, G.J.1
Hoggard, P.G.2
Barry, M.G.3
-
69
-
-
0000491105
-
Phase II trial of lamivudine for chronic hepatitis B
-
69. Tyrell DLJ, Mitchell MC, De Man RA, et al. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 1993; 18: 112(A)
-
(1993)
Hepatology
, vol.18
-
-
Tyrell, D.L.J.1
Mitchell, M.C.2
De Man, R.A.3
-
70
-
-
0032499913
-
A one year trial of lamivudine for chronic hepatitis B
-
70. Lai CL, Chien RN, Leung NWY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998: 339 (2); 61-8
-
(1998)
N Engl J Med
, vol.339
, Issue.2
, pp. 61-68
-
-
Lai, C.L.1
Chien, R.N.2
Leung, N.W.Y.3
|